Logo image of ESPR

ESPERION THERAPEUTICS INC (ESPR) Stock Fundamental Analysis

NASDAQ:ESPR - Nasdaq - US29664W1053 - Common Stock

2.08  -0.07 (-3.26%)

Fundamental Rating

3

Taking everything into account, ESPR scores 3 out of 10 in our fundamental rating. ESPR was compared to 195 industry peers in the Pharmaceuticals industry. ESPR may be in some trouble as it scores bad on both profitability and health. ESPR is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ESPR has reported negative net income.
In the past year ESPR has reported a negative cash flow from operations.
ESPR had negative earnings in each of the past 5 years.
ESPR had a negative operating cash flow in each of the past 5 years.
ESPR Yearly Net Income VS EBIT VS OCF VS FCFESPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of ESPR (-27.62%) is comparable to the rest of the industry.
ESPR's Return On Invested Capital of 8.77% is amongst the best of the industry. ESPR outperforms 87.63% of its industry peers.
Industry RankSector Rank
ROA -27.62%
ROE N/A
ROIC 8.77%
ROA(3y)-88.82%
ROA(5y)-70.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ESPR Yearly ROA, ROE, ROICESPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400

1.3 Margins

ESPR has a better Operating Margin (5.57%) than 79.57% of its industry peers.
ESPR has a Gross Margin of 81.58%. This is amongst the best in the industry. ESPR outperforms 87.10% of its industry peers.
ESPR's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 5.57%
PM (TTM) N/A
GM 81.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.07%
GM growth 5YN/A
ESPR Yearly Profit, Operating, Gross MarginsESPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

1

2. Health

2.1 Basic Checks

ESPR has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ESPR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ESPR has been increased compared to 5 years ago.
Compared to 1 year ago, ESPR has a worse debt to assets ratio.
ESPR Yearly Shares OutstandingESPR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
ESPR Yearly Total Debt VS Total AssetsESPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -5.01, we must say that ESPR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.01, ESPR is not doing good in the industry: 66.13% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.01
ROIC/WACC0.88
WACC9.96%
ESPR Yearly LT Debt VS Equity VS FCFESPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M -400M

2.3 Liquidity

A Current Ratio of 1.85 indicates that ESPR should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.85, ESPR is doing worse than 62.37% of the companies in the same industry.
A Quick Ratio of 1.37 indicates that ESPR should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.37, ESPR is not doing good in the industry: 70.43% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.37
ESPR Yearly Current Assets VS Current LiabilitesESPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 73.11% over the past year.
The Revenue has grown by 187.12% in the past year. This is a very strong growth!
ESPR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.03% yearly.
EPS 1Y (TTM)73.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.46%
Revenue 1Y (TTM)187.12%
Revenue growth 3Y-20.03%
Revenue growth 5YN/A
Sales Q2Q%52%

3.2 Future

ESPR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.47% yearly.
Based on estimates for the next years, ESPR will show a very strong growth in Revenue. The Revenue will grow by 58.03% on average per year.
EPS Next Y85.61%
EPS Next 2Y46.52%
EPS Next 3Y32.4%
EPS Next 5Y29.47%
Revenue Next Year190.11%
Revenue Next 2Y88.48%
Revenue Next 3Y61.33%
Revenue Next 5Y58.03%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ESPR Yearly Revenue VS EstimatesESPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
ESPR Yearly EPS VS EstimatesESPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 -4 -6 -8 -10

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

ESPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 6.69, the valuation of ESPR can be described as very cheap.
ESPR's Price/Forward Earnings ratio is rather cheap when compared to the industry. ESPR is cheaper than 94.62% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.44. ESPR is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 6.69
ESPR Price Earnings VS Forward Price EarningsESPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ESPR is valued a bit cheaper than 79.03% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 32.85
ESPR Per share dataESPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ESPR's earnings are expected to grow with 32.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.52%
EPS Next 3Y32.4%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ESPR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ESPERION THERAPEUTICS INC

NASDAQ:ESPR (1/22/2025, 11:43:00 AM)

2.08

-0.07 (-3.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners70.46%
Inst Owner Change-0.2%
Ins Owners0.43%
Ins Owner Change-0.29%
Market Cap409.84M
Analysts78.67
Price Target7.27 (249.52%)
Short Float %16.5%
Short Ratio4.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-29.71%
Min EPS beat(2)-75.67%
Max EPS beat(2)16.24%
EPS beat(4)2
Avg EPS beat(4)138%
Min EPS beat(4)-75.67%
Max EPS beat(4)613.01%
EPS beat(8)5
Avg EPS beat(8)73.37%
EPS beat(12)8
Avg EPS beat(12)52.17%
EPS beat(16)10
Avg EPS beat(16)37.99%
Revenue beat(2)1
Avg Revenue beat(2)25.52%
Min Revenue beat(2)-1.37%
Max Revenue beat(2)52.41%
Revenue beat(4)3
Avg Revenue beat(4)30.64%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)61.33%
Revenue beat(8)6
Avg Revenue beat(8)16.81%
Revenue beat(12)8
Avg Revenue beat(12)12.55%
Revenue beat(16)9
Avg Revenue beat(16)4.67%
PT rev (1m)-5.02%
PT rev (3m)-6.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.31%
EPS NY rev (1m)0%
EPS NY rev (3m)-63.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.81%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-6.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.69
P/S 1.39
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 32.85
EPS(TTM)-0.64
EYN/A
EPS(NY)0.31
Fwd EY14.96%
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS1.5
BVpS-1.88
TBVpS-1.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.62%
ROE N/A
ROCE 11.1%
ROIC 8.77%
ROICexc 368.88%
ROICexgc 374.84%
OM 5.57%
PM (TTM) N/A
GM 81.58%
FCFM N/A
ROA(3y)-88.82%
ROA(5y)-70.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.07%
GM growth 5YN/A
F-Score6
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 15.94
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 1.37
Altman-Z -5.01
F-Score6
WACC9.96%
ROIC/WACC0.88
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.46%
EPS Next Y85.61%
EPS Next 2Y46.52%
EPS Next 3Y32.4%
EPS Next 5Y29.47%
Revenue 1Y (TTM)187.12%
Revenue growth 3Y-20.03%
Revenue growth 5YN/A
Sales Q2Q%52%
Revenue Next Year190.11%
Revenue Next 2Y88.48%
Revenue Next 3Y61.33%
Revenue Next 5Y58.03%
EBIT growth 1Y110.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year131.46%
EBIT Next 3Y31.09%
EBIT Next 5Y62.8%
FCF growth 1Y86.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.45%
OCF growth 3YN/A
OCF growth 5YN/A